Official ESCRS | European Society of Cataract & Refractive Surgeons
Vienna 2018 Delegate Registration Programme Exhibition Virtual Exhibition Satellites 2018 Survey

 

escrs app advert

The visual outcomes of presbyopia treatment with asymmetrical refractive LENTIS Mplus using mix-and-match methods

Search Title by author or title

Session Details

Session Title: Presented Poster Session: Equipment, Instrumentation & Surgical Devices

Venue: Poster Village: Pod 1

First Author: : M.Tai TAIWAN

Co Author(s): :                           

Abstract Details

Purpose:

To evaluate the clinical results of presbyopia treatment with LENTIS Mplus in cataract patients using the mix and match approach.

Setting:

Department of Ophthalmology, Tri-Service General Hospital, Taipei, Taiwan

Methods:

Retrospective data of cataract patients with binocular Lentis Mplus IOLs (MF 30 in one eye and MF 15 in the fellow eye), were analyzed. The main outcomes measures were uncorrected distance visual acuity, uncorrected intermediate and near visual acuity bilaterally, contrast sensitivity, and complications. Follow up was three months. Glare, halos, independence from glasses, the patient’s satisfaction were assessed.

Results:

The study comprised 60 eyes of 30 patients. The mean age of the patients was 60.7 years (range: 48-71 years). All of the patients achieved a binocular UDVA of 6/7.5 (0.1 logMAR) or better 3 months postoperatively. The mean binocular UNVA was 0.15±0.12 logMAR at 3 months. Contrast sensitivity test were within normal limit in ninety percent of patients and no severe dysphotopsia requiring an IOL exchange. Binocular glare and halos were mild. Patient’s satisfaction was high with 100% of patients willing to recommend the procedure.

Conclusions:

The asymmetrical refractive LENTIS Mplus with mix and match approach provided excellent distance, intermediate and near visual acuity in cataract patients with presbyopia. The postoperative complication rate was low and patient’s satisfaction was high in terms of visual quality.

Financial Disclosure:

None

Back to previous